Comparative effect of body-mass index on outcome with targeted therapy and immunotherapy in patients with metastatic renal cell carcinoma (mRCC)
Year: 2018
Type: article
Abstract: Background: A previous study identified an association between high body mass index (BMI) and better overall survival (OS) in mRCC patients treated with vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKIs) (Albiges et al JCO 2016). We assessed whether the effect of BMI on OS extended beyond VEGF-TKI to immunotherapy (IO) or VEGF/IO combination regimens.
Source: Annals of Oncology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2897722295